Mologic and Neglected Diseases Bedfordshire, UK, May 13 2021: Neglected Tropical Diseases affect more than one billion people worldwide, in some of the poorest areas. According to the World Health Organisation, schistosomiasis is a disease of poverty that leads to chronic ill health and affects nearly 240m [...]
Supported by US initiative to accelerate development and manufacturing including regulatory guidance Advanced diagnostic technology and fully integrated proprietary design requires no specialist training and can be performed at home Bedfordshire, UK, 06 April 2021: Mologic, a leading developer of lateral flow and rapid diagnostic technologies, today announced its [...]
York and Bedfordshire, UK, 17 March 2021: Aptamer Group, the developer of diagnostic and therapeutic Optimer reagents, today announced a commercial partnership with Mologic, a leading developer and manufacturer of lateral flow and rapid diagnostic tests. The partnership will work towards CE marking of Aptamer Group’s AptaDx SARS-CoV-2 lateral [...]
Partnership to accelerate CE marking of Avacta’s SARS-CoV-2 rapid antigen test and support COVID-19 testing in low and middle income countries Cambridge & Wetherby and Bedfordshire, UK, 8th February 2021: Avacta Group plc (AIM: AVCT) (“Avacta”), the developer of Affimer® biotherapeutics and reagents, and Mologic Ltd (“Mologic”) today announced [...]
Preliminary results show 92% sensitivity and 100% specificity, compared with RT-PCR Bedfordshire, UK, 24 December 2020: Mologic Ltd, a leading developer of lateral flow and rapid diagnostic technologies, is pleased to announce its professional-use COVID-19 Rapid Antigen Test has been certified with a CE mark, following independent assessment by [...]
Test will enable diagnosis of liver fluke exposure in livestock in 10 minutes, to target treatment, prevent drug resistance and reduce costly production losses Bedfordshire, UK, 15 December 2020: Mologic Ltd, a leading developer of lateral flow and rapid diagnostic technologies, today announced it is in the final developmental [...]
BotrytisAlert harnesses Mologic’s expert lateral flow technology to enable earlier disease intervention and prevent wide-spread crop failures Developed with funding from Innovate UK as part of the Company’s wider crop protection diagnostic portfolio Bedfordshire, UK, 8th October 2020: Mologic Ltd, a leading developer of lateral flow and rapid [...]
Mark Davis, CEO, Mologic: “Our involvement in Heathrow Airport’s trial for rapid point of care COVID-19 testing solutions is an exciting, and necessary, step towards getting the UK safely travelling again. As experts in lateral flow technology, our Antigen Test is designed to provide results in 10 minutes, supporting [...]
Mologic is pleased to announce that, following successful independent validation by the Liverpool School of Tropical Medicine (LSTM) and St George’s, University of London, our professional-use rapid diagnostic test for COVID-19 has been certified with a CE mark and is ready for manufacture and global distribution. The “triple antibody” [...]
BioSure joins forces with Mologic on production of COVID-19 Antibody self-test Innovative design suitable for at home, self-test giving result in 10 minutes Final validations underway ahead of mass production UK, 11 May 2020: Mologic Ltd, a leading developer of diagnostic technologies, have announced today [...]
Mologic is pleased to announce that following rigorous independent assessment by St George’s, University London and Liverpool School of Tropical Medicine, our point-of-need, professional use, rapid diagnostic test (RDT) for COVID-19 has achieved preliminary clinical performance data of 98% sensitivity at days 14-21 and specificity of 96%. The test [...]
Construction has begun on a new diagnostic manufacturing site, which will have capacity to produce up to 40 million tests per year The first products to be manufactured will be rapid COVID-19 diagnostic tests The new facility is a legally separate social enterprise with a mission to deliver diagnostics [...]